Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

AC220 for Children With Relapsed/Refractory ALL or AML

Phase 1

Completed

Conditions: Lymphoblastic Leukemia, Acute, Childhood
Myelogenous Leukemia, Acute, Childhood

Interventions: Drug: AC220
Drug: Cytarabine
Drug: Etoposide
Drug: Methotrexate

First Posted Date: 2011-08-08

Last Posted Date: 2022-04-04

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 24

Registration Number: NCT01411267

Locations: 🇺🇸
Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States
🇺🇸
Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, United States
🇺🇸
Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States

and more 8 locations

Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Phase 1

Terminated

Conditions: Adult B Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia

Interventions: Drug: Cytarabine
Biological: Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2011-08-03

Last Posted Date: 2019-09-06

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 18

Registration Number: NCT01408160

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Phase 2

Completed

Conditions: Neurotoxicity
Radiation Toxicity
Chemotherapeutic Agent Toxicity
Cognitive/Functional Effects
Lymphoma

Interventions: Biological: Rituximab
Drug: Cytarabine
Drug: Methotrexate
Drug: Procarbazine
Drug: Vincristine
Radiation: low-dose whole-brain radiation therapy

First Posted Date: 2011-07-21

Last Posted Date: 2023-07-20

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 91

Registration Number: NCT01399372

Locations: 🇺🇸
Fresno Cancer Center, Fresno, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 42 locations

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: AC220
Drug: daunorubicin
Drug: cytarabine

First Posted Date: 2011-07-11

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 19

Registration Number: NCT01390337

Locations: 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Phase 1

Recruiting

Conditions: High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Recurrent Burkitt Lymphoma
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Burkitt-Like Lymphoma With 11q Aberration
Recurrent B Acute Lymphoblastic Leukemia
High Grade B-Cell Lymphoma, Not Otherwise Specified
Refractory B Acute Lymphoblastic Leukemia
Refractory Burkitt Lymphoma
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Interventions: Biological: Blinatumomab
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Biological: Inotuzumab Ozogamicin
Drug: Methotrexate
Other: Laboratory Biomarker Analysis
Drug: Mercaptopurine
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine

First Posted Date: 2011-06-13

Last Posted Date: 2024-07-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 276

Registration Number: NCT01371630

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Myeloid Sarcoma
Leukemia Cutis
Myeloid Neoplasm

Interventions: Drug: Asparaginase
Drug: Daunorubicin Hydrochloride
Drug: Cytarabine
Drug: Bortezomib
Other: Laboratory Biomarker Analysis
Drug: Etoposide
Drug: Mitoxantrone Hydrochloride
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Sorafenib Tosylate

First Posted Date: 2011-06-13

Last Posted Date: 2024-10-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1645

Registration Number: NCT01371981

Locations: 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸
Blank Children's Hospital, Des Moines, Iowa, United States
🇺🇸
Albany Medical Center, Albany, New York, United States

and more 217 locations

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Adult Acute Lymphoblastic Leukemia in Complete Remission
Burkitt Leukemia
Burkitt Lymphoma
Childhood Acute Lymphoblastic Leukemia in Complete Remission
Acute Lymphoblastic Leukemia
CD20 Positive
Lymphoblastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Biological: Ofatumumab
Drug: Vincristine Sulfate

First Posted Date: 2011-06-01

Last Posted Date: 2021-05-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 72

Registration Number: NCT01363128

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Dexamethasone
Drug: Cytarabine
Drug: Methotrexate
Drug: 6-Mercaptopurine
Drug: Rituximab
Drug: Prednisone
Drug: L-asparaginase

First Posted Date: 2011-05-23

Last Posted Date: 2014-05-20

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 100

Registration Number: NCT01358253

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years

Phase 4

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2011-05-23

Last Posted Date: 2022-01-19

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 100

Registration Number: NCT01358201

Locations: 🇪🇸
Hospital de Alcorcón, Alcorcón, Spain
🇪🇸
Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸
Fundación Hospital Alcorcón, Alcorcón, Spain

and more 70 locations

Antiangiogenic Therapy for Children with Recurrent Medulloblastoma, Ependymoma and ATRT

Phase 2

Recruiting

Conditions: Medulloblastoma Recurrent
ATRT Recurrent
Ependymoma Recurrent

First Posted Date: 2011-05-19

Last Posted Date: 2024-10-21

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 100

Registration Number: NCT01356290

Locations: 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States

and more 19 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy